- Home
- IVD
- By Technology Types
- By Diseases Types
- By Product Types
- Research
- Resource
- Distributors
- Company
| Product Name | Cyclodextrin-Based Solubilization Agent, Hydroxypropyl-β-Cyclodextrin, 20% Solution |
| Catalog No. | ATR-SDS-0026 |
| Description | Ready-to-use 20% w/v aqueous solution of hydroxypropyl-β-cyclodextrin (HP-β-CD) for solubilization of hydrophobic small molecules, cholesterol depletion from cell membranes, and enhancement of bioavailability in cell-based and in vivo studies. HP-β-CD is a cyclic oligosaccharide consisting of seven glucopyranose units with hydroxypropyl substitution that creates a hydrophilic exterior and hydrophobic interior cavity. The cavity (diameter ~6.0-6.5 angstrom) forms non-covalent inclusion complexes with hydrophobic guest molecules, dramatically increasing their aqueous solubility. HP-β-CD is preferred over native β-cyclodextrin due to its >50-fold higher aqueous solubility and reduced nephrotoxicity. |
| Intended Use | Solubilization and delivery of hydrophobic drugs, fluorescent probes, and natural products in cell culture and animal studies; cholesterol manipulation in membrane biology research; formulation excipient for poorly soluble compounds. |
| Principle / Technology | Hydrophobic cavity of HP-β-CD forms 1:1 or 1:2 host-guest inclusion complexes with lipophilic molecules; outer hydrophilic hydroxypropyl groups enable aqueous solubility; equilibrium binding releases guest molecule at cell membrane. |
| Detection Method | Mix compound (as powder or DMSO stock) with 20% HP-β-CD solution; vortex or sonicate 5-15 minutes; filter through 0.22 µm if precipitation observed; dilute into culture medium to desired working concentration; include vehicle control. |
| Sample Type | Hydrophobic small molecules (logP 2-6), fluorescent probes, sterols, fat-soluble vitamins, polyunsaturated fatty acids. |
| Performance Range / Specifications | Solubility enhancement: 10-1000 fold vs. aqueous buffer depending on guest molecule; typical guest loading 5-15% w/w drug-to-CD; inclusion complex formation >80% for suitable guests. |
| Sensitivity / LOD | Detectable solubilization of compounds with aqueous solubility <1 µg/mL; host cavity size compatible with molecules MW 200-500 Da. |
| Specificity | HP-β-CD preferentially complexes with hydrophobic molecules fitting the 6.0-6.5 Å cavity; selectivity depends on molecular size, shape, and hydrophobicity; cholesterol has very high HP-β-CD affinity (Kd ~10-6 M). |
| Reaction Conditions / Protocol | Inclusion complex formation is a reversible equilibrium process; guest release occurs upon dilution or competitive displacement; no chemical modification of guest molecule. |
| Components / Formulation | Hydroxypropyl-β-cyclodextrin 20% w/v in sterile water for injection; 0.2 µm filtered. |
| Storage Conditions | Store at room temperature (15-25 °C); protect from microbial contamination after opening. |
| Shelf Life | 24 months from date of manufacture in unopened container. |
| Package Specifications | 10 mL, 50 mL, 100 mL sterile bottles. |
| Product Form | Clear, colorless to pale yellow viscous liquid. |
| Quality Control | Each lot tested for HP-β-CD concentration (refractive index), osmolality, pH, sterility, endotoxin <0.1 EU/mL, and solubilization capacity using a standard panel of hydrophobic test compounds. |
| Key Features | Ready-to-use 20% solution; enhanced aqueous solubility vs. native β-cyclodextrin; low hemolytic activity; cell culture tested; 0.2 µm sterile-filtered; cholesterol depletion/cholesterol loading compatible. |
| Purity | HP-β-CD ≥98%; average degree of substitution 4.5-5.5 hydroxypropyl groups per cyclodextrin molecule; β-cyclodextrin <0.5%; 1,2-propanediol <0.1%. |
| Concentration | 20% w/v (200 mg/mL) in water. |
| Activity / Unit Definition | Cholesterol solubilization capacity: ~5 mg cholesterol per gram HP-β-CD from cell membranes. |
| Molecular Weight | Average ~1,396 Da (heptakis-O-(2-hydroxypropyl)-β-cyclodextrin with DS ~4.5). |
| Source / Origin | Derived from corn starch via enzymatic conversion to cyclodextrin followed by chemical hydroxypropylation. |
| pH Range / Optimal pH | pH 5.0-7.0 at 25 °C. |
| Shipping Conditions | Ambient temperature. |
| Expiration Date / Stability | 24 months unopened; after opening, aliquot aseptically and store at 2-8 °C for up to 3 months. |
| Regulatory / Compliance | For research use only; HP-β-CD is an FDA-approved excipient for pharmaceutical formulations (Captisol/Kleptose). Not for human use without appropriate pharmaceutical-grade certification. |
| Compatibility | Compatible with aqueous buffers, cell culture media (DMEM, RPMI-1640), and serum-containing media. HP-β-CD extracts cholesterol from cell membranes at concentrations >5 mM (0.7% w/v) — use lower concentrations when cholesterol depletion is undesirable. Compatible with serum proteins at typical working concentrations. |
| Recommended Buffer System | Not buffered; aqueous solution at native pH 5.0-7.0. |
| Application Notes / Precautions | For cholesterol depletion: incubate cells with 5-10 mM HP-β-CD (0.7-1.4% w/v) in serum-free medium for 30-60 minutes at 37 °C. For cholesterol loading: pre-complex cholesterol with HP-β-CD (cholesterol:HP-β-CD molar ratio 1:6-1:10) before adding to cells. For drug solubilization, optimize HP-β-CD concentration to minimize total volume while maintaining drug solubility. Filter through 0.22 µm to remove undissolved compound aggregates. |
| Batch-to-Batch Consistency | HP-β-CD content within ±5% of specification; osmolality within ±10%; endotoxin <0.1 EU/mL per lot. |
For research use only, not for clinical use.
|
There is no product in your cart. |
Copyright © 2026 Alta DiagnoTech. All rights reserved.
